HOME >> MEDICINE >> NEWS
Insulin sensitizer has anti-inflammatory effect in diabetics

SAN FRANCISCO -- A drug used widely as an insulin sensitizer appears also to have a significant anti-inflammatory effect in diabetics, a property that could make it useful in helping to prevent heart disease in these patients, a study by endocrinologists at the University at Buffalo has found.

Results of the research, involving the drug rosiglitazone, were presented here today (June 15, 2002) at the annual meeting of the American Diabetes Association. Rosiglitazone is sold under the brand name Avandia(r).

UB endocrinologists, led by Paresh Dandona, M.D., professor of medicine and head of the Division of Endocrinology in the UB School of Medicine and Biomedical Sciences, have been studying the anti-inflammatory properties of insulin and insulin sensitizers and their potential use in treatment and prevention of atherosclerosis, one of the leading causes of heart attacks.

Atherosclerosis, or hardening of the arteries, begins as an inflammation of the blood-vessel wall. Persons with diabetes are at increased risk of developing atherosclerosis and heart disease. Dandona's lab has shown in research with a small group of obese non-diabetic volunteers that rosiglitazone decreased the levels of oxygen free radicals which can begin the inflammation cascade by injuring blood-vessel linings. The drug also decreased the levels of several blood markers of inflammation.

The current study involved 11 obese patients with Type 2 diabetes. In this disease, also referred to as adult-onset diabetes, the body produces adequate amounts of insulin, but cells don't respond to its action. Rosiglitazone is prescribed to break down this resistance to insulin.

Researchers collected blood samples from the diabetic volunteers and started them on a six-week course of daily rosiglitazone. They repeated the blood sampling four times during the six weeks of treatment and again at 12 weeks, and analyzed the samples for concentration of three inflammatory markers and fo
'"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-5000 x1417
University at Buffalo
15-Jun-2002


Page: 1 2

Related medicine news :

1. Insulin resistance intervention after stroke focus of $33 million grant
2. Audio conference: Insulin resistance and polycystic ovary syndrome
3. Insulin pumps effective for children with diabetes
4. Insulin pump benefits preschoolers with diabetes
5. Insulin decreases inflammation, aids clot-busting drugs in heart attack patients, UB study shows
6. Insulin-producing cells found in a variety of tissues in diabetes
7. Insulin pump effective for infants, children
8. Insulin precursor linked with increased stroke risk; may represent new risk factor
9. Compound That Mimics Insulin Might Lead To Pill For Diabetes, As Reported In The 7 May Issue Of Science
10. Insulin Resistance And Obesity Avoided In Genetically Modified Mice, As Reported In Science
11. Encapsulating Insulin-Producing Cells For Possible Diabetes Therapy

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Insulin sensitizer has anti inflammatory effect diabetics

(Date:3/6/2015)... Protein identification is increasingly being ... science research including drug discovery, diagnostics, immunology and ... was valued at $1,569.00 million in 2014 and ... 10.63% to reach $2,600.28 million in 2019. , ... protein based on protein size, shape, sequence and ...
(Date:3/6/2015)... As healthcare providers create one ... from disparate systems, they are using OnBase by ... efficiency. Enterprise content management (ECM) solutions ... IT solutions, including electronic medical records (EMR), enterprise ... , The following organizations have recently integrated ...
(Date:3/6/2015)... March 06, 2015 Saving Moses, a ... the world is traveling to Angola, Africa March 7-14 ... their malnutrition program. , This will be the organizations ... Angola, demonstrating their commitment to the region’s population by ... team will engage with the mothers and babies of ...
(Date:3/6/2015)... 06, 2015 Follow us on ... pharmacokinetics of a drug refers to testing of absorption, ... an organism. When toxicity studies are clubbed together with ... ADME/Tox. Increasing focus on lowering costs and time during ... worldwide. The traditional drug development model uses toxicity and ...
(Date:3/6/2015)... March 06, 2015 “On Tap” takes the ... the grand stage, to the silver screen and to modern ... precision toe-tapping numbers and their famous eye-high kicks! Producers, directors ... rich history of tap dancing in this robust show, showcasing ... of the United States. , “On Tap” is proud ...
Breaking Medicine News(10 mins):Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 2Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 3Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 3Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
(Date:3/6/2015)... , March 6, 2015  Palatin Technologies, Inc. (NYSE MKT: ... 27 th Annual ROTH Conference on Wednesday, March 11, ... held at the Ritz Carlton Laguna Niguel in ... Spana , Ph.D., President and Chief Executive Officer of Palatin ... programs. About Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Hospira, Inc. ... Food and Drug Administration (FDA) on today,s FDA approval of ... . This is a watershed moment for improving patient access ... leading global provider of biosimilars, Hospira has seen first-hand the ... a proud participant in these early stages of the development ...
(Date:3/6/2015)... March 6, 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the ... diseases and cancer, today announced that James A. ... present a corporate overview at the 27th Annual ROTH ... time.  Aethlon was previously scheduled to present at 5:30 ... will be held at The Ritz-Carlton Hotel in ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
Cached News: